

## OPIPZA - (2MG, 5MG, 10MG ; Film)

<b>Generic Name</b>	ARIPIPRAZOLE	<b>Innovator</b>	Xiamen LP Pharma
<b>Dosage</b>	2MG, 5MG, 10MG ; Film	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	OPIPZA is an atypical antipsychotic indicated for: ? treatment of schizophrenia in patients ages 13 years and older ? adjunctive treatment of major depressive disorder (MDD) in adults ? irritability associated with autistic disorder in pediatric patients 6 years and older ? treatment of Tourette's disorder in pediatric patients 6 years and older		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.